Trial Profile

A 72-week randomized clinical trial comparing the safety and efficacy of three initial antiretroviral regimens -GPO-VIR S (d4T/3TC/NVP) for 24 weeks followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/stavudine/nevirapine; Lamivudine/zidovudine/nevirapine; Nevirapine
Indications HIV infections
Focus Adverse reactions

28 May 2015 Biomarkers information updated
07 Dec 2012 Results published in Antiviral Therapy.
04 May 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com